MT8的个人主页 - 老虎社区

MT8

MT8

暂无个人介绍

IP属地：未知

3关注

3粉丝

0主题

0勋章

2021-12-23

To the Moon...😆

Novavax says COVID vaccine triggers immune response to Omicron variant

2021-12-04

Hopeless...[sigh]

Alibaba shares fell nearly 9%, hitting a 52 week low

2021-11-17

All approved and ship out soon! :)

Philippines approves emergency use of Novavax COVID-19 vaccine

2021-10-21

Read Law Firm Alert:https://finance.yahoo.com/news/nvax-alert-did-lose-money-131900388.html

2021-10-20

Great ariticle, would you like to share it?

Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate

2021-10-20

https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality

抱歉，原内容已删除

2021-10-20

$Novavax(NVAX)$Read this urgent news - https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3575026781055696,"uuid":"3575026781055696","gmtCreate":1614010939159,"gmtModify":1634736464694,"name":"MT8","pinyin":"mt8","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":3,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.69%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.04","exceedPercentage":"93.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691538542,"gmtCreate":1640219313921,"gmtModify":1640219314035,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the Moon...😆","listText":"To the Moon...😆","text":"To the Moon...😆","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691538542","repostId":"2193511315","repostType":2,"repost":{"id":"2193511315","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640215949,"share":"https://www.laohu8.com/m/news/2193511315?lang=&edition=full","pubTime":"2021-12-23 07:32","market":"us","language":"en","title":"Novavax says COVID vaccine triggers immune response to Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2193511315","media":"Reuters","summary":"Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response agai","content":"<p>Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant.</p>\n<p>Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.</p>\n<p>Novavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.</p>\n<p>\"We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax's president of research and development.</p>\n<p>Other COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.</p>\n<p>Novavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.</p>\n<p>The drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.</p>\n<p>The company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax's vaccine. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax says COVID vaccine triggers immune response to Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax says COVID vaccine triggers immune response to Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 07:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant.</p>\n<p>Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.</p>\n<p>Novavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.</p>\n<p>\"We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax's president of research and development.</p>\n<p>Other COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.</p>\n<p>Novavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.</p>\n<p>The drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.</p>\n<p>The company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax's vaccine. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193511315","content_text":"Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant.\nNovavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.\nNovavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.\n\"We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax's president of research and development.\nOther COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.\nNovavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.\nThe drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.\nThe company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax's vaccine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601477889,"gmtCreate":1638553239349,"gmtModify":1638553239349,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hopeless...[sigh]&nbsp;","listText":"Hopeless...[sigh]&nbsp;","text":"Hopeless...[sigh]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601477889","repostId":"1192973257","repostType":2,"repost":{"id":"1192973257","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638542620,"share":"https://www.laohu8.com/m/news/1192973257?lang=&edition=full","pubTime":"2021-12-03 22:43","market":"us","language":"en","title":"Alibaba shares fell nearly 9%, hitting a 52 week low","url":"https://stock-news.laohu8.com/highlight/detail?id=1192973257","media":"老虎资讯综合","summary":"Alibaba shares fell nearly 9%&nbsp;in morning trading, hitting a 52 week low.","content":"<p>Alibaba shares fell nearly 9%&nbsp;in morning trading, hitting a 52 week low.</p>\n<p><img src=\"https://static.tigerbbs.com/bffdf13d46c5b423e7d19ca33abd1d05\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba shares fell nearly 9%, hitting a 52 week low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba shares fell nearly 9%, hitting a 52 week low\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-03 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alibaba shares fell nearly 9%&nbsp;in morning trading, hitting a 52 week low.</p>\n<p><img src=\"https://static.tigerbbs.com/bffdf13d46c5b423e7d19ca33abd1d05\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192973257","content_text":"Alibaba shares fell nearly 9% in morning trading, hitting a 52 week low.","news_type":1},"isVote":1,"tweetType":1,"viewCount":584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878964107,"gmtCreate":1637140195078,"gmtModify":1637140197735,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"All approved and ship out soon! :)","listText":"All approved and ship out soon! :)","text":"All approved and ship out soon! :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878964107","repostId":"2184833364","repostType":2,"repost":{"id":"2184833364","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637125658,"share":"https://www.laohu8.com/m/news/2184833364?lang=&edition=full","pubTime":"2021-11-17 13:07","market":"us","language":"en","title":"Philippines approves emergency use of Novavax COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2184833364","media":"Reuters","summary":"MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by N","content":"<p>MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc , its food and drug agency chief said on Wednesday, the ninth vaccine approved in the Southeast Asian country.</p>\n<p>The nanoparticle vaccine, under the brand name Covovax, will be manufactured by Serum Institute of India, and is approved for use on adults 18 and above, the agency's chief Rolando Enrique Domingo told a public briefing.</p>\n<p>Covovax, which had efficacy of 89.7% in clinical trials, will be administered in two doses not less than 21 days apart, Domingo added.</p>\n<p>The Philippines has inoculated more than a quarter of its 110 million population.</p>\n<p>Early this month, Novavax received its first emergency use authorisation&nbsp;from Indonesia. Novavax also filed an application for approval of the vaccine in Canada and with the European Medicines Agency.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philippines approves emergency use of Novavax COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilippines approves emergency use of Novavax COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-17 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc , its food and drug agency chief said on Wednesday, the ninth vaccine approved in the Southeast Asian country.</p>\n<p>The nanoparticle vaccine, under the brand name Covovax, will be manufactured by Serum Institute of India, and is approved for use on adults 18 and above, the agency's chief Rolando Enrique Domingo told a public briefing.</p>\n<p>Covovax, which had efficacy of 89.7% in clinical trials, will be administered in two doses not less than 21 days apart, Domingo added.</p>\n<p>The Philippines has inoculated more than a quarter of its 110 million population.</p>\n<p>Early this month, Novavax received its first emergency use authorisation&nbsp;from Indonesia. Novavax also filed an application for approval of the vaccine in Canada and with the European Medicines Agency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184833364","content_text":"MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc , its food and drug agency chief said on Wednesday, the ninth vaccine approved in the Southeast Asian country.\nThe nanoparticle vaccine, under the brand name Covovax, will be manufactured by Serum Institute of India, and is approved for use on adults 18 and above, the agency's chief Rolando Enrique Domingo told a public briefing.\nCovovax, which had efficacy of 89.7% in clinical trials, will be administered in two doses not less than 21 days apart, Domingo added.\nThe Philippines has inoculated more than a quarter of its 110 million population.\nEarly this month, Novavax received its first emergency use authorisation from Indonesia. Novavax also filed an application for approval of the vaccine in Canada and with the European Medicines Agency.","news_type":1},"isVote":1,"tweetType":1,"viewCount":594,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853417332,"gmtCreate":1634828985309,"gmtModify":1634867886731,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Read Law Firm Alert:https://finance.yahoo.com/news/nvax-alert-did-lose-money-131900388.html","listText":"Read Law Firm Alert:https://finance.yahoo.com/news/nvax-alert-did-lose-money-131900388.html","text":"Read Law Firm Alert:https://finance.yahoo.com/news/nvax-alert-did-lose-money-131900388.html","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853417332","isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859779830,"gmtCreate":1634738662029,"gmtModify":1634738846822,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859779830","repostId":"1139162424","repostType":2,"repost":{"id":"1139162424","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634737086,"share":"https://www.laohu8.com/m/news/1139162424?lang=&edition=full","pubTime":"2021-10-20 21:38","market":"us","language":"en","title":"Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1139162424","media":"Tiger Newspress","summary":"Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its v","content":"<p>Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate.<img src=\"https://static.tigerbbs.com/3d4824b49a33a4c30dc1920ee98b9387\" tg-width=\"765\" tg-height=\"366\" width=\"100%\" height=\"auto\">According to reports, Novavax has been unable to consistently prove&nbsp;it&nbsp;can manufacture a vaccine shot that meets the required&nbsp;quality standards.</p>\n<p>The Food and Drug Administration discusses&nbsp;purity levels with each manufacturer,&nbsp;but each&nbsp;batch of the COVID-19 vaccine is&nbsp;supposed to be&nbsp;at least 90% pure.</p>\n<p>Novavax has reportedly struggled to maintain purity levels that are close to the 90% threshold. The company recently showed purity levels around the 70% range, per reports.&nbsp;</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate.<img src=\"https://static.tigerbbs.com/3d4824b49a33a4c30dc1920ee98b9387\" tg-width=\"765\" tg-height=\"366\" width=\"100%\" height=\"auto\">According to reports, Novavax has been unable to consistently prove&nbsp;it&nbsp;can manufacture a vaccine shot that meets the required&nbsp;quality standards.</p>\n<p>The Food and Drug Administration discusses&nbsp;purity levels with each manufacturer,&nbsp;but each&nbsp;batch of the COVID-19 vaccine is&nbsp;supposed to be&nbsp;at least 90% pure.</p>\n<p>Novavax has reportedly struggled to maintain purity levels that are close to the 90% threshold. The company recently showed purity levels around the 70% range, per reports.&nbsp;</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139162424","content_text":"Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate.According to reports, Novavax has been unable to consistently prove it can manufacture a vaccine shot that meets the required quality standards.\nThe Food and Drug Administration discusses purity levels with each manufacturer, but each batch of the COVID-19 vaccine is supposed to be at least 90% pure.\nNovavax has reportedly struggled to maintain purity levels that are close to the 90% threshold. The company recently showed purity levels around the 70% range, per reports.","news_type":1},"isVote":1,"tweetType":1,"viewCount":751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859770739,"gmtCreate":1634738654421,"gmtModify":1634738849915,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","listText":"https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","text":"https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859770739","repostId":"1139162424","repostType":2,"isVote":1,"tweetType":1,"viewCount":397,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859711983,"gmtCreate":1634734152833,"gmtModify":1634736176179,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Read this urgent&nbsp;news - https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Read this urgent&nbsp;news - https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","text":"$Novavax(NVAX)$Read this urgent news - https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859711983","isVote":1,"tweetType":1,"viewCount":978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":691538542,"gmtCreate":1640219313921,"gmtModify":1640219314035,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the Moon...😆","listText":"To the Moon...😆","text":"To the Moon...😆","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691538542","repostId":"2193511315","repostType":2,"repost":{"id":"2193511315","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640215949,"share":"https://www.laohu8.com/m/news/2193511315?lang=&edition=full","pubTime":"2021-12-23 07:32","market":"us","language":"en","title":"Novavax says COVID vaccine triggers immune response to Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2193511315","media":"Reuters","summary":"Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response agai","content":"<p>Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant.</p>\n<p>Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.</p>\n<p>Novavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.</p>\n<p>\"We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax's president of research and development.</p>\n<p>Other COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.</p>\n<p>Novavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.</p>\n<p>The drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.</p>\n<p>The company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax's vaccine. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax says COVID vaccine triggers immune response to Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax says COVID vaccine triggers immune response to Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 07:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant.</p>\n<p>Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.</p>\n<p>Novavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.</p>\n<p>\"We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax's president of research and development.</p>\n<p>Other COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.</p>\n<p>Novavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.</p>\n<p>The drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.</p>\n<p>The company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax's vaccine. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193511315","content_text":"Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant.\nNovavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.\nNovavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.\n\"We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax's president of research and development.\nOther COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.\nNovavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.\nThe drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.\nThe company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax's vaccine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601477889,"gmtCreate":1638553239349,"gmtModify":1638553239349,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Hopeless...[sigh]&nbsp;","listText":"Hopeless...[sigh]&nbsp;","text":"Hopeless...[sigh]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601477889","repostId":"1192973257","repostType":2,"repost":{"id":"1192973257","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638542620,"share":"https://www.laohu8.com/m/news/1192973257?lang=&edition=full","pubTime":"2021-12-03 22:43","market":"us","language":"en","title":"Alibaba shares fell nearly 9%, hitting a 52 week low","url":"https://stock-news.laohu8.com/highlight/detail?id=1192973257","media":"老虎资讯综合","summary":"Alibaba shares fell nearly 9%&nbsp;in morning trading, hitting a 52 week low.","content":"<p>Alibaba shares fell nearly 9%&nbsp;in morning trading, hitting a 52 week low.</p>\n<p><img src=\"https://static.tigerbbs.com/bffdf13d46c5b423e7d19ca33abd1d05\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba shares fell nearly 9%, hitting a 52 week low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba shares fell nearly 9%, hitting a 52 week low\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-03 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alibaba shares fell nearly 9%&nbsp;in morning trading, hitting a 52 week low.</p>\n<p><img src=\"https://static.tigerbbs.com/bffdf13d46c5b423e7d19ca33abd1d05\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192973257","content_text":"Alibaba shares fell nearly 9% in morning trading, hitting a 52 week low.","news_type":1},"isVote":1,"tweetType":1,"viewCount":584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859779830,"gmtCreate":1634738662029,"gmtModify":1634738846822,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859779830","repostId":"1139162424","repostType":2,"isVote":1,"tweetType":1,"viewCount":751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859770739,"gmtCreate":1634738654421,"gmtModify":1634738849915,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","listText":"https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","text":"https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859770739","repostId":"1139162424","repostType":2,"isVote":1,"tweetType":1,"viewCount":397,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859711983,"gmtCreate":1634734152833,"gmtModify":1634736176179,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Read this urgent&nbsp;news - https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Read this urgent&nbsp;news - https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","text":"$Novavax(NVAX)$Read this urgent news - https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859711983","isVote":1,"tweetType":1,"viewCount":978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853417332,"gmtCreate":1634828985309,"gmtModify":1634867886731,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Read Law Firm Alert:https://finance.yahoo.com/news/nvax-alert-did-lose-money-131900388.html","listText":"Read Law Firm Alert:https://finance.yahoo.com/news/nvax-alert-did-lose-money-131900388.html","text":"Read Law Firm Alert:https://finance.yahoo.com/news/nvax-alert-did-lose-money-131900388.html","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853417332","isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878964107,"gmtCreate":1637140195078,"gmtModify":1637140197735,"author":{"id":"3575026781055696","authorId":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"All approved and ship out soon! :)","listText":"All approved and ship out soon! :)","text":"All approved and ship out soon! :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878964107","repostId":"2184833364","repostType":2,"isVote":1,"tweetType":1,"viewCount":594,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}